0000000000155144

AUTHOR

Robinson S

showing 3 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016

2018

Background: The lifetime risk of stroke has been calculated in a limited number of selected populations. We sought to estimate the lifetime risk of stroke at the regional, country, and global level using data from a comprehensive study of the prevalence of major diseases.Methods: We used the Global Burden of Disease (GBD) Study 2016 estimates of stroke incidence and the competing risks of death from any cause other than stroke to calculate the cumulative lifetime risks of first stroke, ischemic stroke, or hemorrhagic stroke among adults 25 years of age or older. Estimates of the lifetime risks in the years 1990 and 2016 were compared. Countries were categorized into quintiles of the sociode…

MalePercentileNutrition and DiseaseDisease030204 cardiovascular system & hematologyGlobal HealthSocioeconomic FactorGlobal Burden of Disease0302 clinical medicinepreventionVoeding en ZiekteCause of DeathGlobal healthStrokePOPULATIONCause of deathAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceMedicine (all)11 Medical And Health SciencesGeneral MedicineMiddle Agedlifetime riskstroke3142 Public health care science environmental and occupational health3. Good healthStrokeGBD 2016 Lifetime Risk of Stroke CollaboratorsFemaleBURDENLife Sciences & BiomedicineResearch ArticleHumanAdultRiskPopulationGlobal Burden of Disease (GBD)03 medical and health sciencesMedicine General & InternalAge DistributionGeneral & Internal MedicinemedicineHumansLife SciencePoint estimationcardiovascular diseasesSex DistributioneducationVLAGAgedScience & TechnologyHYPERTENSIONbusiness.industrymedicine.diseaseSocioeconomic Factorsbusiness030217 neurology & neurosurgeryRCDemography
researchProduct

Global, regional, and national burden of stroke, 1990-2016

2019

Background: Stroke is a leading cause of mortality and disability worldwide and the economic costs of treatment and post-stroke care are substantial. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic, comparable method of quantifying health loss by disease, age, sex, year, and location to provide information to health systems and policy makers on more than 300 causes of disease and injury, including stroke. The results presented here are the estimates of burden due to overall stroke and ischaemic and haemorrhagic stroke from GBD 2016. Methods: We report estimates and corresponding uncertainty intervals (UIs), from 1990 to 2016, for incidence, preval…

MaleCost effectivenessIMPACTGlobal HealthGUIDELINES3124 Neurology and psychiatryBrain IschemiaGlobal Burden of DiseaseCOST-EFFECTIVENESS0302 clinical medicineRisk FactorsGlobal healthPrevalenceMedicine030212 general & internal medicineStrokePOPULATIONAged 80 and overRISKeducation.field_of_studyIncidence (epidemiology)Mortality rateIncidenceAge FactorsMiddle AgedPREVALENCEStrokeFemaleLife Sciences & BiomedicineIntracranial HemorrhagesAdultPopulationClinical Neurology03 medical and health sciencesHumanseducationAgedScience & TechnologyNeurology & Neurosurgerybusiness.industry3112 NeurosciencesKlinisk medicin1103 Clinical Sciencesmedicine.diseaseGBD 2016 Stroke CollaboratorsVerbal autopsyTRANSIENT ISCHEMIC ATTACKYears of potential life lostSocioeconomic FactorsHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesbusinessPRIMARY PREVENTION030217 neurology & neurosurgeryDemographyRCLancet Neurology
researchProduct